• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About Us
  • Contact Us
  • Our Google News Channel
IRA vs 401k

IRA vs 401k

Retirement Options

  • Home
  • Roth IRA
  • Roth 401k
  • SEP IRA
  • Simple IRA
  • 401K
  • Finanace
You are here: Home / Finanace / This Coronavirus Stock Has Over 80% Upside, Says J.P. Morgan

This Coronavirus Stock Has Over 80% Upside, Says J.P. Morgan

December 11, 2020 by Retirement

Covid-19 has been responsible for a complete shift in how society operates. On a lighter note, it has also brought with it a whole new world of terminology. For investors there has been the addition of the term, “coronavirus stocks.” Those are the names which have come to the fore during the pandemic, offering potential vaccines and therapeutics to help us get back to normal.

Novavax (NVAX) is possibly the ultimate “coronavirus stock.” It has certainly been the most profitable. The vaccine specialist’s shares have appreciated by a humongous 2790% throughout the year, as investors have pinned their hopes on the company’s Covid-19 vaccine candidate NVX-CoV2373.

But with several of its rivals already nearing the finish line with their respective vaccine candidates, will Novavax be remembered for just delivering massive returns or does it still have a meaningful part to play in the rollout of global Covid-19 vaccines?

For J.P. Morgan analyst Eric Joseph, the answer is the latter.

“We continue to view NVX-CoV2373 as having a well-differentiated positioning in the overall COVID-19 vaccine space, both clinically and logistically, and believe current levels under-reflect its long-term commercial potential,” Joseph said.

Joseph rates NVAX an Overweight (i.e. Buy) along with a $215 price target. The implication for investors? Upside of ~87%. (To watch Joseph’s track record, click here)

The latest endorsement comes despite a delay to NVX-CoV2373’s U.S. & Mexico Phase 3 study. However, following the FDA’s positive review of the Phase 2 data, all that remains is the agency’s review of Novavax’ commercial-scale production at the North Carolina facility, for the trial to be given the go ahead. This should happen in the coming weeks.

Meanwhile, NVX-CoV2373’s Phase 3 U.K. trial and phase 2b study in South Africa are both fully enrolled, with efficacy readouts slated for 1Q21.

“While the trial is expected to primarily support approvability in major ex-US markets,” joseph said, “Given the standardized trial protocol across the COVID-19 vaccine space, the company believes a robust data set (with consistent data in the SA study) could potentially support a faster regulatory pathway in the US as well.”

Looking at the consensus breakdown, based on 4 Buys and 1 Sell, Novavax gets a Moderate Buy rating. The analysts’ forecast is for ~62% of upside, given the average price target clocks in at $186.20. (See NVAX stock analysis on TipRanks)

To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Filed Under: Finanace

Primary Sidebar

E-mail Newsletter

More to See

Maximizing Your Retirement Savings: Expert Insights on IRAs and 401(k)s

November 23, 2024 By Roth

IRA vs 401(k): Key Differences to Help You Choose the Best Retirement Plan for 2024

November 21, 2024 By Roth

Real Estate Syndication in Indianapolis: Unlocking Investment Potential

November 15, 2024 By Retirement

Maximizing Your 401k at 55 | Retirement Strategies for Growth

October 15, 2024 By Roth

401(k) savings

Retirement Savings Options: Navigating the Path to a Secure Future

August 15, 2024 By SEO Robot

Retirement Planning

August 13, 2024 By Roth

Infographic comparing IRA vs 401(k) retirement options.

IRA and 401(k): Compare Your Retirement Options

May 20, 2024 By SEO Robot

Tags

401(k) 401(k) advantages 401(k) insights 401k at 55 401k growth strategies best retirement plan catch-up contributions exclusive listings Financial Planning financial planning 2024 Financial Security future planning Indianapolis property market Investing Investment Investment Options Investment Strategies IRA IRA benefits IRA strategies IRA vs 401k Labrosse Real Estate luxury homes luxury real estate maximize retirement savings multi-family investment Indianapolis passive income through real estate Personal Finance premium properties property syndication real estate investment real estate syndication Indianapolis Retirement retirement advice retirement investment Retirement Planning retirement planning 2024 Retirement Savings retirement savings tips retirement strategies retirement tips Savings secure retirement secure retirement funds Wealth Management

Footer

  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms of Use
  • Google News

Recent

  • Roth IRA Contribution and Income Limits for 2025
  • Maximizing Your Retirement Savings: Expert Insights on IRAs and 401(k)s
  • IRA vs 401(k): Key Differences to Help You Choose the Best Retirement Plan for 2024
  • Real Estate Syndication in Indianapolis: Unlocking Investment Potential
  • Maximizing Your 401k at 55 | Retirement Strategies for Growth